In New York, Pfizer created four little research units in 2010, San Diego, San Francisco, and Boston located close to several highest Academic Medical Centers (AMCs), or hospitals with adjoining medical schools.
The aim of these units was to redesign collaboration with the function of developing new, advanced drugs candidates for testing in patients with Pfizer and academic medical research workers. Project teams consisted of Pfizer scientists and professors working side-by-side to cut back the time needed to bring a therapeutic drug from the laboratory to a patient's bedside.
This case explores the academic cooperation model developed by Pfizer. How would the model evolve later on? And how would new, similar collaboration versions surface at other leading pharmaceutical companies introduce a danger to the Pfizer model?
Pfizer's Centers for Therapeutic Innovation (CTI) case study solution
PUBLICATION DATE: September 02, 2014 PRODUCT #: 615024-PDF-ENG
This is just an excerpt. This case is about TECHNOLOGY & OPERATIONS
Related Case Solutions & Analyses:
GPS-To-Go Takes on Garmin
The HLB Turnaround
Digital Chocolate
British Petroleum (PLC) and John Browne: Culture of Risk Beyond Petroleum (A)
Exercise: Challenging Operational Assumptions
IBMs On Demand Business Strategy
Motorola-Penang
Apollo Hospitals: Differentiation through Hospitality
Chartwell Technologies: Upping the Ante with Internet Poker
Remote Access and Networking Technologies for SMEs
